BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals (BCRX) has disclosed a new risk, in the Brand / Reputation category. BioCryst Pharmaceuticals faces a risk that the sale o...

Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value

BioCryst Pharmaceuticals (($BCRX)) has held its Q4 earnings call. Read on for the main highlights of the call. BioCryst Pharmaceuticals’ latest ear...

BioCryst Earnings Call Highlights Profits, Pipeline Momentum

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quoin Pharmaceuticals (QNRX – Research Report), Biod...

Analysts Are Bullish on These Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Biodesix (BDSX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enovis (ENOV – Research Report) and BioCryst (BCRX –...

Analysts Are Bullish on These Healthcare Stocks: Enovis (ENOV), BioCryst (BCRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioCryst (BCRX – Research Report) and Fate Therape...

Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE)

An update from BioCryst ( ($BCRX) ) is now available. BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and co...

BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance

Evercore ISI analyst Gavin Clark-Gartner resumed coverage with a Buy rating on BioCryst yesterday and set a price target of $17.00. The company’s s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCRX	$8.22	-1.91%	5.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BCRX	$8.22	-1.9%	5.03M
3
4
5
6

BCRX

BCRX

Get BioCryst Pharmaceuticals Inc. Data in Excel

Get BioCryst Pharmaceuticals Inc. Data in Excel